Prestige Consumer Healthcare (PBH) Set to Announce Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) will be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.09 per share for the quarter. Prestige Consumer Healthcare has set its FY25 guidance at $4.40-4.46 EPS and its FY 2025 guidance at 4.400-4.460 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The company had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm’s revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.06 earnings per share. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $73.79 on Tuesday. The company has a market capitalization of $3.66 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.08 and a beta of 0.47. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a 12 month low of $56.61 and a 12 month high of $75.80. The stock has a 50 day moving average of $72.19 and a 200 day moving average of $69.62.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PBH. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

Check Out Our Latest Analysis on PBH

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Further Reading

Earnings History for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.